U.S. License Holder:
Eli Lilly and Co.
Date of License:
April-21-2014
Last Update:
Dec-15-2024
FDA-Approved Indications
CYRAMZA (ramucirumab) is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated:
As a single agent or in combination with paclitaxel, for treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy;
In combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations;
In combination with docetaxel, for treatment of metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy;
In combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine;
As a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of greater than or equal to 400 ng/mL and have been treated with sorafenib.